ONC catalyst calendar

BeOne Medicines Ltd.

Upcoming catalysts
47
Cash runway
Cash generating
Cash & investments
$5098M
Phase 3 programs
16

BeOne Medicines Ltd. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.

The next scheduled catalyst is A Study to Investigate the Effect of the CYP3A Inducer Phenytoin and the CYP3A Inhibitor Itraconazole on the Pharmacokinetics of BGB-58067 in Healthy Participants on October 31, 2026. There are 47 upcoming events on record.

BeOne Medicines Ltd. generates cash from operations, so a burn-based runway figure does not apply.

Across 9 concluded trials, 44% reached completion rather than being terminated or withdrawn.

Upcoming catalysts

DateEventTypePhase
October 31, 2026 A Study to Investigate the Effect of the CYP3A Inducer Phenytoin and the CYP3A Inhibitor Itraconazole on the Pharmacokinetics of BGB-58067 in Healthy Participants Trial Milestone Phase 1
November 15, 2026 A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemia Trial Milestone Phase 2
November 15, 2026 A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma Trial Milestone Phase 1/Phase 2
November 22, 2026 A Trial in Healthy Participants to Assess Drug Interaction Potential of BGB-43395 Trial Milestone Phase 1
November 30, 2026 A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple-Ascending Doses of Tacabrutideg (BGB-16673) in Adults With Chronic Spontaneous Urticaria and in Healthy Participants Trial Milestone Phase 1
December 31, 2026 A First-in-Human (FIH) Study of BG-C137, an Anti-Fibroblast Growth Factor Receptor 2b (FGFR2b) Antibody Drug Conjugate, in Participants With Advanced Solid Tumors Trial Milestone Phase 1
December 31, 2026 A Study to Evaluate Long-term Safety of Zanubrutinib Regimens in Participants With B-Cell Malignancies Who Participated in BeiGene Parent Studies of Zanubrutinib Trial Milestone Phase 3
February 8, 2027 A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Sonrotoclax in Participants With Severe Hepatic Impairment Trial Milestone Phase 1
March 15, 2027 A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies Trial Milestone Phase 1/Phase 2
March 31, 2027 A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors Trial Milestone Phase 1/Phase 2
May 31, 2027 Study of Bcl-2 Inhibitor Sonrotoclax (BGB-11417) in Participants With Mature B-Cell Malignancies Trial Milestone Phase 1
July 1, 2027 A Study to Investigate the Relative Bioavailability of 2 Tablet Formulations and the Effect of Food on the Pharmacokinetics of BGB-58067 in Healthy Participants Trial Milestone Phase 1
July 30, 2027 BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer Trial Milestone Phase 1
July 31, 2027 A Study to Investigate Safety, Tolerability, and Pharmacokinetics of Tacabrutideg (BGB-16673) in Participants With Moderate and Severe Hepatic Impairment Trial Milestone Phase 1
September 28, 2027 Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors Trial Milestone Phase 1
September 30, 2027 An Investigational Study of BGB-58067 As a Single Agent and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors Trial Milestone Phase 1
October 15, 2027 A Study to Examine the Efficacy and Safety of Zanubrutinib Given to Adults With Primary Membranous Nephropathy Trial Milestone Phase 2/Phase 3
October 30, 2027 A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Trial Milestone Phase 3
November 1, 2027 A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors Trial Milestone Phase 1
December 31, 2027 A Study of BG-C477 in Participants With Advanced Solid Tumors Trial Milestone Phase 1
February 28, 2028 A Study Investigating Alternate Schedules of Tislelizumab Plus Chemotherapy in Japanese Patients With First-line Advanced ESCC Trial Milestone Phase 2
April 17, 2028 A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Trial Milestone Phase 3
April 29, 2028 A Study of BGB-B455 in Adults With Advanced or Metastatic Solid Tumors Trial Milestone Phase 1
May 15, 2028 A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors Trial Milestone Phase 3
July 15, 2028 A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma Trial Milestone Phase 3
August 8, 2028 A Study to Evaluate the Safety of BG-A3004 in Healthy Participants and Patients With Immune-Mediated Skin Diseases Trial Milestone Phase 1
August 31, 2028 A Study of BGB-11417 in Participants With Myeloid Malignancies Trial Milestone Phase 1/Phase 2
August 31, 2028 A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL) Trial Milestone Phase 3
September 30, 2028 A First-in-Human Study Investigating BG-85738 Alone or in Combination With Other Antitumor Agents in Patients With Advanced or Metastatic Solid Tumors With Rat Sarcoma Virus (RAS) Mutations Trial Milestone Phase 1
September 30, 2028 An Investigational Study of BG-75202 Alone and in Combination With Other Agents in Patients With Myeloid Malignancies Trial Milestone Phase 1
September 30, 2028 Study of BG-T187 Alone and in Combination With Other Therapeutic Agents in Participants With Advanced Solid Tumors Trial Milestone Phase 1
November 1, 2028 A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors Trial Milestone Phase 1
December 2, 2028 A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies Trial Milestone Phase 1/Phase 2
February 28, 2029 A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors Trial Milestone Phase 1
April 15, 2029 BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease Trial Milestone Phase 3
April 30, 2029 A First-in-Human Study of BG-C0979 in Adults With Advanced Solid Tumors Trial Milestone Phase 1
September 21, 2029 Study Comparing BGB-B2033 With Sorafenib or Lenvatinib in Relapsed Hepatocellular Carcinoma Trial Milestone Phase 3
September 30, 2029 An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors Trial Milestone Phase 1
September 30, 2029 A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL) Trial Milestone Phase 3
November 30, 2029 Efficacy and Safety of BG-C9074 With Bevacizumab Compared With Bevacizumab in Adults With Ovarian, Fallopian Tube, or Primary Peritoneal Cancers Trial Milestone Phase 3
November 30, 2029 A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers. Trial Milestone Phase 1/Phase 2
November 30, 2029 A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors Trial Milestone Phase 3
December 15, 2029 BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors Trial Milestone Phase 1
April 30, 2030 A Study of Sonrotoclax (BGB-11417) in Children With Relapsed or Refractory Acute Myeloid Leukemia and B-cell Acute Lymphoblastic Leukemia Trial Milestone Phase 1/Phase 2
February 15, 2031 A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia Trial Milestone Phase 3
December 31, 2031 A Study to Evaluate Efficacy and Safety of Tislelizumab Plus Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma in Racial and Ethnic Minority Patients in the United States Trial Milestone Phase 2
February 15, 2032 Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL) Trial Milestone Phase 3

Track ONC alongside other companies. Add it to a watchlist and see every catalyst on one calendar.

Open ONC in the tracker

Recent history

DateEventTypePhase
September 27, 2026 A Study to Investigate the Relative Bioavailability and Food Effect of Tablet for Oral Suspension of Sonrotoclax in Healthy Adults Trial Milestone Phase 1
September 22, 2026 A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia Trial Milestone Phase 2
August 26, 2026 Quarterly results filed (8-K) Earnings —
August 5, 2026 Quarterly results filed (8-K) Earnings —
June 26, 2026 8-K filed: Other event Filing —
June 11, 2026 8-K filed: Leadership change Corporate —
June 8, 2026 A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies Trial Milestone Phase 1
May 23, 2026 Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies Trial Milestone Phase 3
May 15, 2026 8-K filed: Other event Filing —
May 15, 2026 A First-in-Human Study of BGB-C354 Alone and in Combination With Tislelizumab in Participants With Advanced Solid Tumors Trial Milestone Phase 1
May 6, 2026 Quarterly results filed (8-K) Earnings —
April 27, 2026 A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation Trial Milestone Phase 3
April 23, 2026 BGB-43395 Alone or as Part of Combination Therapies in Chinese Participants With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors Trial Milestone Phase 1
April 23, 2026 A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification Trial Milestone Phase 1
April 21, 2026 A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer Trial Milestone Phase 1
April 14, 2026 Quarterly results filed (8-K) Earnings —
April 13, 2026 An Investigational Study of BG-89894 Tablets in Participants With Advanced Solid Tumors Trial Milestone Phase 1
April 9, 2026 A Study of BGB-R046 as Monotherapy and in Combination With Tislelizumab in Solid Tumors Trial Milestone Phase 1
February 26, 2026 Quarterly results filed (8-K) Earnings —
February 23, 2026 A Study to Investigate the Relative Bioavailability and Food Effect of a Fixed-Dose Combination Tablet Containing Zanubrutinib and Sonrotoclax (BG-71332) in Healthy Adults Trial Milestone Phase 1
December 18, 2025 8-K filed: Leadership change Corporate —
November 19, 2025 8-K filed: Material agreement Corporate —
November 6, 2025 Quarterly results filed (8-K) Earnings —
August 29, 2025 Quarterly results filed (8-K) Earnings —
August 25, 2025 8-K filed: Material agreement, Reg FD disclosure Corporate —
August 6, 2025 Quarterly results filed (8-K) Earnings —
July 18, 2025 Study of Sonrotoclax (BGB-11417) Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma Trial Milestone Phase 1/Phase 2
May 7, 2025 Quarterly results filed (8-K) Earnings —
April 29, 2025 8-K filed: Other event Filing —
April 28, 2025 Quarterly results filed (8-K) Earnings —

About this data

Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.

Last updated 2026-10-14.